7 Results for "

renal glucose reabsorption

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "renal glucose reabsorption" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-A0080
CAS No.: 94-16-6
Synonyms: Sodium p-aminohippurate; p-Aminohippuric acid sodium salt
Research Areas:  

Inflammation/Immunology

Aminohippurate sodium (Sodium p-aminohippurate) is a renal tubular transport inhibitor and a substrate for organic anion transporters. Aminohippurate sodium inhibits renal tubular reabsorption of phosphate and promotes increased urinary phosphate excretion. Aminohippurate sodium inhibits renal tubular reabsorption of vitamin C as well as the transport of glucose .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109018B
CAS No.: 1661838-94-3
Purity:  99.43%
Target:  

SGLT

Research Areas:  

Metabolic Disease

Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109018A
CAS No.: 1539295-26-5
Purity:  99.43%
Target:  

SGLT

Research Areas:  

Metabolic Disease

Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
loading...
    loading...
Cat. No.: HY-13414
CAS No.: 329045-45-6
Synonyms: Remogliflozin A
Target:  

SGLT

Research Areas:  

Metabolic Disease

Remogliflozin (Remogliflozin A) is an orally active, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, with a Ki of 12.4 nM for human SGLT2 and 26.0 nM for rat SGLT2. Remogliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption. Without insulin stimulation, remogliflozin suppresses the elevation of plasma glucose, reduces fasting blood glucose and glycated hemoglobin, and improves glycosuria, hyperglycemia, hyperinsulinemia, hypertriglyceridemia and insulin resistance in diabetic rodents. Remogliflozin can be used in research related to type 2 diabetes .
loading...
    loading...
Cat. No.: HY-109018AR
CAS No.: 1539295-26-5
Research Areas:  

Metabolic Disease

Velagliflozin proline (Standard) is the analytical standard of Velagliflozin (proline) (HY-109018A). This product is intended for research and analytical applications. Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
loading...
    loading...
Cat. No.: HY-178734
CAS No.: 1800115-22-3
Target:  

SGLT

Research Areas:  

Metabolic Disease

Janagliflozin is orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50=0.0058 μM for SGLT2 and 4.802 μM for SGLT1). Janagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion (UGE) to lower blood glucose levels. Janagliflozin is promising for research of type 2 diabetes mellitus .
loading...
    loading...
Cat. No.: HY-109018BR
CAS No.: 1661838-94-3
Research Areas:  

Metabolic Disease

Velagliflozin proline hydrate (Standard) is the analytical standard of Velagliflozin (proline hydrate) (HY-109018B). This product is intended for research and analytical applications. Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
loading...
    loading...